Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Public's perspective on COVID-19 adenovirus vector vaccines after thrombosis with thrombocytopenia syndrome (TTS) reports and associated regulatory actions - a cross-sectional study in six EU member states
ID
Buhl, Caroline
(
Author
),
ID
Jacobsen, Ramune
(
Author
),
ID
Birna Almarsdóttir, Anna
(
Author
),
ID
Abtahi, Shahab
(
Author
),
ID
Andersen, Armin
(
Author
),
ID
Deligianni, Elena
(
Author
),
ID
Dermiki-Gkana, Foteini
(
Author
),
ID
Kontogiorgis, Christos
(
Author
),
ID
Kos, Mitja
(
Author
),
ID
Čebron Lipovec, Nanča
(
Author
)
PDF - Presentation file,
Download
(608,88 KB)
MD5: 9A34A9FED40E864D4C017E993A7B8028
URL - Source URL, Visit
https://www.sciencedirect.com/science/article/pii/S0264410X23015116
Image galllery
Abstract
Objective: In 2021, thrombosis with thrombocytopenia syndrome (TTS) was confirmed by the European Medicines Agency (EMA) as a rare side effect of the COVID-19 adenovirus vector vaccines Vaxzevria® and Jcovden®. This study aimed to describe the public’s knowledge of TTS and how it affected the willingness to be vaccinated with COVID-19 vaccines and other vaccines in six European countries. Methods: From June to October of 2022, a multi-country cross-sectional online survey was conducted in Denmark, Greece, Latvia, Netherlands, Portugal, and Slovenia. The minimum target of participants to be recruited was based on the size of the country’s population. The results were analysed descriptively. Results: In total, 3794 respondents were included in the analysis; across the six countries, 33.3 %–68.3 % reported being familiar with signs and symptoms of TTS, although 3.1–61.4 % of those were able to identify the symptoms correctly. The reported changes in willingness to be vaccinated against COVID-19 and with other vaccines varied per country. The largest reported change in the willingness to be vaccinated with Vaxzevria® and Jcovden® was observed in Denmark (61.2 %), while the willingness to be vaccinated with other COVID-19 vaccines changed most in Slovenia (30.4 %). The smallest decrease in willingness towards future vaccination against COVID-19 was reported in the Netherlands (20.9 %) contrasting with the largest decrease observed in Latvia (69.1 %). Conclusion: Knowledge about TTS seemed to have influenced the public’s opinion in Europe resulting in less willingness to be vaccinated with Vaxzevria® and Jcovden®. Willingness for vaccination against COVID-19 with other vaccines and widespread use of vaccines to prevent other diseases also differed and seemed to be determined by the approaches taken by national health authorities when reacting to and communicating about COVID-19 vaccination risks. Further investigation of optimal risk communication strategies is warranted.
Language:
English
Keywords:
public perception
,
COVID-19 vaccines
,
thrombosis with thrombocytopaenia syndrome (TTS)
,
SARS-CoV-2 adenovirus vector vaccines
,
national health policies
,
risk awareness
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
FFA - Faculty of Pharmacy
Publication status:
Published
Publication version:
Version of Record
Year:
2024
Number of pages:
Str. 556-563
Numbering:
Vol. 42, iss. 3
PID:
20.500.12556/RUL-159520
UDC:
614:616.98:578.834
ISSN on article:
0264-410X
DOI:
10.1016/j.vaccine.2023.12.065
COBISS.SI-ID:
179573763
Publication date in RUL:
11.07.2024
Views:
124
Downloads:
30
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Vaccine
Shortened title:
Vaccine
Publisher:
Butterworth Scientific
ISSN:
0264-410X
COBISS.SI-ID:
26585600
Licences
License:
CC BY-NC 4.0, Creative Commons Attribution-NonCommercial 4.0 International
Link:
http://creativecommons.org/licenses/by-nc/4.0/
Description:
A creative commons license that bans commercial use, but the users don’t have to license their derivative works on the same terms.
Secondary language
Language:
Slovenian
Keywords:
javno dojemanje cepiva proti COVID-19
,
tromboza s sindromom trombocitopenije (TTS)
,
vektor adenovirusa SARS-CoV-2
,
nacionalna zdravstvena politika
,
zavedanje o tveganju
,
SARS-CoV-2
,
cepiva
,
COVID-19
,
javno zdravstvo
Projects
Funder:
Other - Other funder or multiple funders
Funding programme:
European Medicines Agency
Project number:
EMA/2018/23/PE
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back